Skip to content Skip to footer

Sanders: Democrats’ Drug Pricing Plan “Goes Nowhere Near as Far as It Should”

Sen. Bernie Sanders suggested that pharmaceutical industry lobbying weakened the proposal.

Senate Budget Committee Chairman Bernie Sanders walks out of the U.S. Capitol after delivering a speech against the CHIPS Act on the floor of the Senate on July 25, 2022, in Washington, D.C.

Senate Budget Committee Chair Bernie Sanders on Tuesday blasted Democrats’ watered-down drug pricing plan and suggested pharmaceutical industry lobbying weakened the proposal.

“It’s a very weak proposal. It goes nowhere near as far as it should,” Sanders (I-Vt.) told NBC News’ Sahil Kapur.

The deal unveiled earlier this month would enable Medicare to negotiate the prices of a limited number of prescription drugs. Other provisions include creating a $2,000 out-of-pocket cap for Medicare Part D beneficiaries, stopping brand-name manufacturers from blocking generic options, and penalizing companies that raise prices faster than inflation.

The plan is notably backed by Sen. Joe Manchin (D-W.Va.) — who last year blocked a House-approved budget reconciliation package and said this month that he wouldn’t support new climate spending or tax hikes on the rich and large corporations.

Sanders, who pushed for a sweeping package last year and has long been a leading Medicare for All advocate, pointed to the U.S. Department of Veterans Affairs (VA) as a model for drug price negotiation.

“The American people want Medicare to negotiate prescription drug prices like the VA does,” the senator said Tuesday, according to The Hill.

“The VA has been doing that for decades. The prices they pay are about half as much as Medicare. This thing will only apply to a certain number of drugs,” Sanders continued, noting that parts of the proposal would not take effect until 2026.

“So it’s a weak proposal. Is it better than nothing? I suppose,” he added of Democrats’ plan.

Sanders also took aim at industry lobbying, specifically calling out the trade group Pharmaceutical Research and Manufacturers of America (PhRMA). As he put it: “We’re dealing with the power of PhRMA over the Congress. They don’t lose very often.”

As Common Dreams reported last week, Big Pharma is mobilizing an army of lobbyists to tank Democrats’ drug reform plan while hiking the price of prescription medications.

“Pharma is spending millions to defeat a very modest drug pricing bill,” Sanders tweeted Friday. “Joe Manchin, who is blocking climate action, is the major recipient of fossil fuel campaign contributions. This is how a corrupt political system works.”

Defying Trump’s right-wing agenda from Day One

Inauguration Day is coming up soon, and at Truthout, we plan to defy Trump’s right-wing agenda from Day One.

Looking to the first year of Trump’s presidency, we know that the most vulnerable among us will be harmed. Militarized policing in U.S. cities and at the borders will intensify. The climate crisis will deteriorate further. The erosion of free speech has already begun, and we anticipate more attacks on journalism.

It will be a terrifying four years to produce social justice-driven journalism. But we’re not falling to despair, because we know there are reasons to believe in our collective power.

The stories we publish at Truthout are part of the antidote to creeping authoritarianism. And this year, we promise we will kick into an even higher gear to give you truthful news that cuts against the disinformation, vitriol, hate and violence. We promise to publish analyses that will serve the needs of the movements we all rely on to survive the next four years, and even build for the future. We promise to be responsive, to recognize you as members of our community with a vital stake and voice in this work.

Please show your support for Truthout with a tax-deductible donation (either once today or on a monthly basis).